Prothena Corp PLC  is a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases that involve protein misfolding or cell adhesion.

Current Report (Form 8-K | Period ending 2024-11-12)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Prothena Corp (PRTA US)

Current Report (Form 8-K | Period ending 2024-11-12)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-09-23)

S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Current Report (Form 8-K | Period ending 2024-08-08)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)